Clinicogenomic characterization of inflammatory breast cancer.

Autor: Priedigkeit N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Harrison B; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Shue R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Hughes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Li Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Kirkner GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Spurr LF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Remolano MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Strauss S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Files J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Feeney AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Grant L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mohammed-Abreu A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garrido-Castro A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Sousa RB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bychkovsky B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA., Nakhlis F; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Bellon JR; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA., King TA; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Lindeman N; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sholl L; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Dillon D; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Overmoyer B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Cherniack A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Lynce F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 May 10. Date of Electronic Publication: 2024 May 10.

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression.

Autor: Nishida J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.; Department of Medicine, Harvard Medical School, Boston, MA 02115., Cristea S; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115., Bodapati S; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215., Puleo J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.; Department of Medicine, Harvard Medical School, Boston, MA 02115., Bai G; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115., Patel A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115., Hughes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115., Snow C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115., Borges V; Medicine-Medical Oncology, University of Colorado Comprehensive Cancer Center, Aurora, CO 80045., Ruddy KJ; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905., Collins LC; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02115., Feeney AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115., Slowik K; The Broad Institute of MIT and Harvard, Cambridge, MA 02138., Bossuyt V; Mass General Pathology, Massachusetts General Hospital, Boston, MA 02114., Dillon D; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.; Department of Medicine, Harvard Medical School, Boston, MA 02115., Partridge AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.; Department of Medicine, Harvard Medical School, Boston, MA 02115., Michor F; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115.; The Broad Institute of MIT and Harvard, Cambridge, MA 02138.; The Ludwig Center at Harvard, Boston, MA 02115.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA 02215., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.; Department of Medicine, Harvard Medical School, Boston, MA 02115.; Mass General Pathology, Massachusetts General Hospital, Boston, MA 02114.; The Ludwig Center at Harvard, Boston, MA 02115.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA 02215.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2023 Dec 05; Vol. 120 (49), pp. e2316763120. Date of Electronic Publication: 2023 Nov 27.

Bacterial excretion rates in the diagnosis of urinary tract infections.

Autor: Feeney JG, Feeney AM

Publikováno v: Irish medical journal [Ir Med J] 1974 Nov 23; Vol. 67 (22), pp. 585-8.